Patent classifications
C12N2502/45
CELL COMPOSITION, METHOD FOR PRODUCING CELL COMPOSITION, AND PHARMACEUTICAL COMPOSITION CONTAINING CELL COMPOSITION
An object of the present invention is to provide a technique for concentrating blood cells having high proliferation ability and/or differentiation ability. The present invention relates to a method for producing a cell composition, the method including: a step of extracting cells expressing a G protein-coupled receptor 56 (GPR56) from a cell aggregate containing immature blood cells, and a cell composition containing an immature blood cell expressing GPR56, in which a proportion of the immature blood cell expressing GPR56 is 50% to 100% of total cells.
EFFICIENT DIFFERENTIATION OF HUMAN STEM CELLS TO DEFINITIVE ENDODERM
The present disclosure provides a medium for cells, such as human stem cells including human induced pluripotent stem cells (iPScs) which medium enhances the formation of definitive endoderm (DE) which in turn can be subsequently directed and differentiated into mature cell types, e.g., pancreas insulin producing cells.
THREE-DIMENSIONAL PRINTED ORGANS, DEVICES, AND MATRICES
Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.
Directed differentiation and maturation of pluripotent cells into hepatocyte like cells by modulation of Wnt-signalling pathway
Provided are improved methods using Glycogen synthase kinase 3 (GSK3) inhibitors by which endodermal cells, notably endodermal cells derived from human pluripotent stem cells (hPS), such as but not limited to hiPS-cells and hES-cells may be differentiated into hepatocyte like cells. The specific modulation of wingless integration gene (WNT)-signalling pathway and use of GSK3 inhibitors achieve direct differentiation and maturation of hepatocytes derived from human pluripotent stem (hPS) cells. GSK-3 inhibitors, when added to the growth medium at certain developmental stages, leads to more mature and functional features for the hepatocyte like cells as well as more pure and homogenous populations of hepatocyte like cells. Provided are also hepatocyte like cells obtained by these methods as well as compositions comprising them.
METHOD FOR REDUCING PLURIPOTENT STEM CELLS, METHOD FOR PRODUCING CELL POPULATION HAVING REDUCED PLURIPOTENT STEM CELLS
The present invention pertains to a method for culturing a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells at a temperature of 40.5 C. or higher and reducing the pluripotent stem cells included in the cell population. The present invention also pertains to a method for reducing pluripotent stem cells from a cell population including pluripotent stem cells and differentiated cells derived from pluripotent stem cells, wherein the method includes a step for activating the TRPV-1 expressed in the pluripotent stem cells included in the cell population. The present invention makes it possible to reduce the pluripotent stem cells remaining in an undifferentiated state when inducing the differentiation of a pluripotent stem cell population.
COMPOSITION INCLUDING ADULT PLURIPOTENT OLFACTORY STEM CELL, METHOD FOR ISOLATING PLURIPOTENT ADULT OLFACTORY STEM CELL, AND USE THEREOF
A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).
OFF-THE-SHELF IPSC-DERIVED CAR-NK CELL AS MONOTHERAPY AND IN COMBINATION WITH ANTIBODY
Provided are methods and compositions for use in cancer immunotherapies. Exemplary compositions include functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. In some embodiments, derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.
METHODS OF GENERATING FUNCTIONAL HUMAN TISSUE
Methods of tissue engineering, and more particularly methods and compositions for generating various vascularized 3D tissues, such as 3D vascularized embryoid bodies and organoids are described. Certain embodiments relate to a method of generating functional human tissue, the method comprising embedding an embryoid body or organoid in a tissue construct comprising a first vascular network and a second vascular network, each vascular network comprising one or more interconnected vascular channels; exposing the embryoid body or organoid to one or more biological agents, a biological agent gradient, a pressure, and/or an oxygen tension gradient, thereby inducing angiogenesis of capillary vessels to and/or from the embryoid body or organoid; and vascularizing the embryoid body or organoid, the capillary vessels connecting the first vascular network to the second vascular network, thereby creating a single vascular network and a perfusable tissue structure.
METHOD FOR EXPANSION AND MAINTENANCE OF NK CELLS FOR IMMUNOTHERAPY
The present invention discloses a method for expansion of natural killer (NK) cells or CAR-NK cells using peripheral blood mononuclear cells (PBMCs) and culturing the cells in a medium comprising a feeder layer having a population of mesenchymal stem cells (MSCs) with disrupted or deleted MHC class I gene and/or MHC class II gene and a heterologous gene for expressing Interleukin-21 (IL-21), and Interleukin-2 (IL-2). The present disclosure further provides a method and a model for evaluating natural killer (NK) cells or CAR-NK cells using tester line comprising induced Pluripotent stem cells (iPSCs) comprising disrupted or deleted MHC class I gene and/or MHC class II gene and a heterologous gene encoding a tumor antigen.
METHODS AND SYSTEMS FOR CONVERTING PRECURSOR CELLS INTO INTESTINAL TISSUES THROUGH DIRECTED DIFFERENTIATION
The generation of complex organ tissues from human embryonic and pluripotent stem cells (PSCs) remains a major challenge for translational studies. It is shown that PSCs can be directed to differentiate into intestinal tissue in vitro by modulating the combinatorial activities of several signaling pathways in a step-wise fashion, effectively recapitulating in vivo fetal intestinal development. The resulting intestinal organoids were three-dimensional structures consisting of a polarized, columnar epithelium surrounded by mesenchyme that included a smooth muscle-like layer. The epithelium was patterned into crypt-like SOX9-positive proliferative zones and villus-like structures with all of the major functional cell types of the intestine. The culture system is used to demonstrate that expression of NEUROG3, a pro-endocrine transcription factor mutated in enteric anendocrinosis is sufficient to promote differentiation towards the enteroendocrine cell lineage. In conclusion, PSC-derived human intestinal tissue should allow for unprecedented studies of human intestinal development, homeostasis and disease.